 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 12 study evaluating Trappsol CycloTM, a proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously IV to 